---
title: "BGI Genomics Co., Ltd (300676.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300676.SZ.md"
symbol: "300676.SZ"
name: "BGI Genomics Co., Ltd"
industry: "Biotechnology"
datetime: "2026-05-19T22:49:32.120Z"
locales:
  - [en](https://longbridge.com/en/quote/300676.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300676.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300676.SZ.md)
---

# BGI Genomics Co., Ltd (300676.SZ)

## Company Overview

BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exome sequencing; epigenetics whole genome bisulfite sequencing and ChIp-Seq; and metagenomics and 16S/18S/ITS sequencing. It also provides RNA sequencing, long non-coding RNA sequencing, small RNA sequencing, iso-seq / pacbio transcriptome sequencing; single cell sequencing and high throughput single cell RNA-Seq; spatial transcriptome-stereo-seq; immune repertoire and pre-made library sequencing; and bioinformatics solutions.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.bgi.com](https://www.bgi.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:10.000Z

**Overall: C (0.54)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 29 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 3.35% |  |
| Net Profit YoY | 40.74% |  |
| P/B Ratio | 1.99 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 16716704736.84 |  |
| Revenue | 3838459601.02 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -6.54% | D |
| Profit Margin | -14.93% | D |
| Gross Margin | 39.71% | B |
| Revenue YoY | 3.35% | C |
| Net Profit YoY | 40.74% | B |
| Total Assets YoY | -9.93% | E |
| Net Assets YoY | -7.54% | D |
| Cash Flow Margin | -26.60% | E |
| OCF YoY | 3.35% | C |
| Turnover | 0.32 | D |
| Gearing Ratio | 24.73% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - BGI Genomics Co., Ltd",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "3.35%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "40.74%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.99",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "16716704736.84",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3838459601.02",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-6.54%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-14.93%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "39.71%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "3.35%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "40.74%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-9.93%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-7.54%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-26.60%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "3.35%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.32",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "24.73%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -29.41 | 63/81 | - | - | - |
| PB | 2.00 | 23/81 | 2.35 | 2.22 | 2.03 |
| PS (TTM) | 4.39 | 13/81 | 5.86 | 5.53 | 5.03 |
| Dividend Yield | 0.00% | - | 0.20% | 0.20% | 0.19% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-27T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 49.15 |
| Highest Target | 52.19 |
| Lowest Target | 52.19 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300676.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300676.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300676.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300676.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**